Your browser doesn't support javascript.
loading
[Update on current care guidelines: ovarian cancer]. / Munasarjasyöpä.
Duodecim ; 128(12): 1300-1, 2012.
Article en Fi | MEDLINE | ID: mdl-22822606
ABSTRACT
Ovarian cancer is the most lethal gynaecological cancer. It appears that seemingly ovarian or primary peritoneal carcinomas, in fact, originate from fimbriae. BRCA1/2 mutation carriers are recommended for the removal of ovaries and fimbriae, to reduce the risk of cancer. Treatment of epithelial ovarian cancer is based on the combination of surgery and chemotherapy. The residual tumour volume at the primary operation is the most important predictive factor of survival. The best response at the primary treatment is observed with combination chemotherapy with taxane and platinum. Adding bevacitzumab to first line chemotherapy may improve survival.
Asunto(s)
Search on Google
Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Guideline / Prognostic_studies Límite: Female / Humans Idioma: Fi Año: 2012 Tipo del documento: Article
Search on Google
Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Guideline / Prognostic_studies Límite: Female / Humans Idioma: Fi Año: 2012 Tipo del documento: Article